Universal Ibogaine Inc.

OTC: IBOGF · Healthcare · Biotechnology

Canadian filerHQ Calgary, ABReports USD

#875 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 27

v0.1 · 5/100 weight · pillars only

↑ operating margin, Piotroski F · ↓ listing tenure, return on equity

Methodology →

Revenue TTM

$1.1M

Rev growth YoY (TTM)

+49.7%

Net income (FY)

-$8.3M

Employees

Market cap

$8.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$843.7k1.1M CAD2022

Net income-$8.3M-10.5M CAD2022

Operating income$391.7k497.2k CAD2022

Total assets$4.9M6.3M CAD2022

Liabilities$1.9M2.4M CAD2022

Equity$3.1M3.9M CAD2022

Revenue trend

FY2018 – FY2022 · USD

FY18

FY19

FY20

FY21

$843.7k

FY22

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Universal Ibogaine Inc. booked $843.7k in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -980.2% net margin.

Peers · Healthcare

Synlogic, Inc.45D AEON Biopharma, Inc.——TransCode Therapeutics, Inc.——Ainos, Inc.41D

Key facts

CEONicholas Peter Karos

SectorHealthcare

IndustryBiotechnology

HeadquartersCalgary, AB

ExchangeOTC: IBOGF

Employees7

IPO date2022-03-01

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.